Balance Sheet (Annual)

AMD / Advanced Micro Devices, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 869,000 549,000 869,000 805,000 785,000 1,264,000 1,185,000
    Marketable Securities Current 896,000 453,000 228,000 235,000 0 - -
    Accounts Receivable Net Current 919,000 630,000 832,000 818,000 533,000 311,000 400,000
    Inventory Net 476,000 562,000 884,000 685,000 678,000 751,000 739,000
    Due From Related Parties Current - - - - - - -
    Prepaid Expense Current - - - - 43,000 63,000 77,000
    Other Assets Current - - - - 248,000 109,000 188,000
    Assets Current 3,229,000 2,265,000 2,884,000 2,736,000 2,320,000 2,530,000 2,622,000
  Property Plant And Equipment Net 726,000 658,000 346,000 302,000 188,000 164,000 261,000
  Goodwill 323,000 553,000 553,000 320,000 278,000 289,000 289,000
  Equity Method Investments - - - - - 59,000 58,000
  Other Assets Noncurrent 249,000 247,000 386,000 344,000 323,000 279,000 310,000
  Assets 4,954,000 4,000,000 4,337,000 3,767,000 3,109,000 3,321,000 3,540,000
Liabilities And Stockholders Equity
  Liabilities Current
    Debt Current - - - - - - -
    Accounts Payable Current 363,000 278,000 519,000 415,000 279,000 440,000 384,000
    Due To Related Parties Current - - - - 245,000 255,000 -
    Accrued Liabilities Current 550,000 489,000 530,000 558,000 472,000 391,000 541,000
    Other Liabilities Current 72,000 63,000 - - 124,000 69,000 57,000
    Liabilities Current 1,774,000 1,397,000 1,618,000 1,440,000 1,403,000 1,346,000 1,486,000
  Long Term Debt Noncurrent - - - 2,025,000 2,025,000 1,435,000 1,325,000
  Other Liabilities Noncurrent 63,000 28,000 177,000 105,000 86,000 124,000 118,000
  Commitments And Contingencies - - - - - - -
  Stockholders Equity
    Stockholders Equity Number Of Shares Par Value And Other Disclosures
      Common Stock Value 7,000 7,000 7,000 8,000 8,000 9,000 9,000
      Additional Paid In Capital Common Stock 6,672,000 6,803,000 6,894,000 6,949,000 7,017,000 8,334,000 8,464,000
      Treasury Stock Value 107,000 109,000 112,000 119,000 123,000 119,000 108,000
    Retained Earnings Accumulated Deficit -4,977,000 -6,160,000 -6,243,000 -6,646,000 -7,306,000 -7,803,000 -7,760,000
    Accumulated Other Comprehensive Income Loss Net Of Tax -5,000 -3,000 -2,000 -5,000 -8,000 -5,000 6,000
    Stockholders Equity 1,590,000 538,000 544,000 187,000 -412,000 416,000 611,000
  Liabilities And Stockholders Equity 4,954,000 4,000,000 4,337,000 3,767,000 3,109,000 3,321,000 3,540,000

Peers - Semiconductors and Related Devices (3674)

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 007903107